Table 6 Comparison of LRR patterns between previous studies and the present study in patients without PMRT
Study | Treatment decade | No. of patients | Tumor stage | N stage | Axillary dissection | The median number of ALNs dissected | Adjuvant chemotherapy (regimens) | Endocrine therapy | Anti-Her2targeted therapy | LRR type (No. of patients) | CW | SCN | Axillary | IMN | Regional | Local + Regional |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Truong, P. T. et al. [12] | 1989–1999 | 1505 | 60.7%T1 39.3%T2 | N0 | 100% | 10 | 20.8% | 48.4% | – | First (89) | 68.5% | 19.1% | 24.7% | 3.4% | 31.5% | 15.7% |
Abi-Raad, R. et al. [11] | 1980–2004 | 1136 | 75.3%T1 24.7%T2 | N0 | 90% | 14 | 14.6% | 56.6% | – | First (58) | 72.4% | 13.8% | 10.3% | 6.9% | 27.6% | 1.7% |
Hastings, J. et al. [13] | 1994–2004 | 1259 | T1 | N0 | – | 11 | 24.2% | 77.7% | – | Accumulated (33) | 75.8% | 9.1% | 27.3% | 0.0% | 24.2% | 12.1% |
Li, J. L. et al. [14] | 2001–2008 | 353 | 45.6%T1 54.4%T2 | N0 | 100% | – | 100% | unless contraindicated or intolerant |  – | First (39) | 53.8% | 48.7% | 10.3% | 2.6% | 46.2% | 15.4% |
Sharma, Ranjna et al. [19] | 1997–2002 | 1019 | 78.8%T1 21.2%T2 | 73.9%N0 26.1%N1 | 68.1% | 16 | 41.6% (94.7% anthracycline- and/or taxane-based) | 87.2% |  – | Accumulated (23) | 52.1% | 39.2% | 4.3% | 17.4% | 47.8% | 4.3% |
Jwa, E. et al. [20] | 2002–2011 | 390 | 58.5%T1 41.5%T2 | 78.7%N0 21.3%N1 | – | 6 | 54.4% (100% anthracycline- and/or taxane-based) | 95.0% | 8.9% | Accumulated (12) | 50.0% | 33.3% | 33.3% | 8.3% | – | – |
Asaga, S. et al. [21] | – | 428 | 49.5%T1 51.5%T2 | N1 | 98.6% | 16 | 67% (100% anthracycline- and/or taxane-based) | – | 22.0% | First (20) | 50.0% | 35.0% | 20.0% | 5.0% | – | 5.0% |
wallgren et al. [22] | 1978–1993 | 5352 | T1–3N0–3 (41%T1) | 24%N0 45%N1 31%N2/3 | – | ≥8 | for high-risk patients (CMF) | Most post-menopausal patients with N+ |  – | First (1138) | 53% | 26% | 13% | 1% |  – | 7% (multiple sites) |
Katz et al. [23] | 1975–1994 | 1031 | II-III (80%T1–2 10%T3 10%Tx) | 14%N0 45%N1 26%N2 15%N3 | 100% | 17 | 100% (96% anthracycline- based) | 68.2% |  – | Accumulated (179) | 68% | 47% | 14% | 8% |  – |  – |
Rangan, A. M. et al. [24] | 1980–1991 | 217 | 88.5%T1–2 7.8%T3 3.7%Tx | 76%N1 24%N2 | 100% | 14 | 100% (82%CMF) | 50% |  – | First (42) | 52.4% | 40.5% | 14.3% | 7.1% | 47.6% | 9.5% |
Taghian, A et al. [25] | 1984–1994 | 5758 |  – | 51.4%N1 32.2%N2 16.1%N3 | 100% | 16 | 100% (90.3% anthracycline- based) |  – |  – | Isolated (715) | 56.9% | 22.6% | 11.7% | <1% | – | – |
Nielsen et al. [26] | 1982–1990 | 1545 | II-III |  – | – | ≥5 | 55.4%CMF |  – | – | Isolated (456) | 57% | 14% | 45% | 0% | 43% | 11% |
Macdonald et al. [27] | 1990–2004 | 165 | T1–2N1 | – | 100% | 14 | 62% | >90% | – | Accumulated (13) | 77% | 23% | 38% | – | – | – |
Trovo et al. [28] | 1999–2005 | 150 | I-II | 54%N0 8%N1mic 37%N1a | 97.3% | 18 | 38.7% (75.9% anthracycline- based) | >90% | – | Accumulated (17) | 64.7% | 64.7% | – | – | – | 29.4% |
Muhsen, S et al. [29] | 1995–2006 | 924 | T1–2N1 | – | 94% | 18 | 86% (76% anthracycline- and/or taxane-based) | 100% | 41% | First (56) | 62.5% | 25.0% | 17.9% | 5.4% | 37.5% | 8.9% |
Chen et al. [30] | 2001–2007 | 390 | T1–2N0–1 Triple-negative | 78.7%N0 21.3%N1 | 100% | – | 86.4% (79.2% anthracycline- based) | – | – | Accumulated (31) | 41.9% | 29.0% | 0.0% | 6.5% | – | 22.6% |
Kuo et al. [31] | – | 115 | 91.5%T1–2 | – | – | – | – | – | – | Isolated (115) | 65% | 25% | 15% | 0% | – | – |
Skinner et al. [32] | 1994–2006 | 159 | 91.5%T1–2 13.2%T3–4 4.4%Tx | 50.9%N0 32.7%N1 8.8%N2 5.0%N3 | 89% | – | 61.6% | 69.6% | – | Isolated (159) | 77% | 27% | 13% | 4% | – | – |
Ma et al. [33] | 2005–2013 | 235 | 91.5%T1–2 | 54.9%N0 33.6%N1 11.5%N2/3 | 100% | 12 | 92.8% (83.9% anthracycline- and/or taxane-based) | 94.6% | 6.7% | Isolated (235) | 48.5% | 44.7% | 14.0% | 18.3% | 51.5% | 13.2% |
Strom, E. A. et al. [5] | 1975–1994 | 1031 | 83%T1–2 10%T3 7%Tx | 14%N0 45%N1 41%N2/3 | 100% | 17 | doxorubicin-based | – | – | Accumulated (180) | 67% | 43% | 12% | – | 53% | – |
Current study | 1999–2014 | 7073 | 65.1%T1–2N0 29.7%T1–2N1 5.2%III | 65.1%N0 30.3%N1 4.6%N2/3 | 95.2% | 19 | 75.6% (86.9% anthracycline- and/or taxane-based) | 84.4% | 22.9% | Accumulated (469) | 50.7% | 50.3% | 19.6% | 10.7% | 67.2% | 17.9% |